$22.96
-0.54-2.3%
Ult. Agg.: Oct 23, 4:00 PM
Collegium Pharmaceutical (COLL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Collegium Pharmaceutical (COLL) ha pubblicato l'ultima guidance il agosto 6, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $825M - $855M per il periodo.
Rispetto alle previsioni precedenti, Collegium Pharmaceutical ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Collegium Pharmaceutical ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Collegium Pharmaceutical. 23
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.70 | $1.46 | $2.09 | $1.79 |
| Actual | $1.92 | $1.76 | $2.04 | $2.25 |
| Surprise | +12.9% | +20.5% | -2.39% | +25.7% |
| Revenue | ||||
| Estimate | $202.3M | $183.7M | $207.3M | $189.4M |
| Actual | $199.9M | $193.5M | $205.4M | $209.4M |
| Surprise | -1.19% | +5.32% | -0.88% | +10.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.79 | $1.92 | $1.07 | $1.22 |
| Revenue | ||||
| Consensus | $215.8M | $223.6M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.92 | $1.70 | 12.9 % |
| Q1 | May 7, 2026 | $1.76 | $1.46 | 20.5 % |
| Q4 | Feb 26, 2026 | $2.04 | $2.09 | -2.39 % |
| Q3 | Nov 6, 2025 | $2.25 | $1.79 | 25.7 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $199.88M | $202.28M | -1.19 % |
| Q1 | May 7, 2026 | $193.52M | $183.74M | 5.32 % |
| Q4 | Feb 26, 2026 | $205.45M | $207.28M | -0.88 % |
| Q3 | Nov 6, 2025 | $209.36M | $189.36M | 10.6 % |